RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events
....drug resistance remains an unresolved problem with ADCs, and there is interest in developing better-tolerated and more effective therapeutics for breast cancer.
"HER2-positive breast cancer remains an aggressive disease with historically poor outcomes. HER2-targeted ADCs have emerged as a promising strategy for breast cancer treatment, with a particular focus on enhancing outcomes for both patients with HER2-positive and HER2-Low breast cancer. The development of T-DM1 and T-DXd has significantly improved patient outcomes, but resistance and progression still occur. Additionally, with these novel drug mechanisms come additional side effects and toxicities that must be carefully monitored, specifically thrombocytopenia and elevated liver function enzymes for T-DM1 and gastrointestinal effects, alopecia, and pneumonitis for T-DXd."
The exploration of novel sequences and combinations (such as oncolytic virus + immune checkpoint inhibitors) incorporating ADCs represents another promising frontier in cancer therapy. These combinations have the potential to expand the therapeutic reach, overcome resistance mechanisms, modulate the immune system, and offer tailored treatments to specific patient subgroups. Ongoing clinical trials and research efforts are essential in advancing our understanding of optimal sequential approaches and combinations and their potential to improve patient outcomes in the complex landscape of cancer treatment.
https://www.mdpi.com/2072-6694/16/4/800